Ovagen (20 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: one subcutaneous injection daily for the full 16 weeks. At 10 mg/mL, 1 unit on a U-100 syringe delivers 100 mcg, so every dose in this protocol lands at or under 1.5 units, which is 0.015 mL. That is why the master sheet calls for 30-unit or 50-unit insulin syringes rather than 100-unit barrels: the finer graduations make those fractions readable. Titration is slow, 10 to 20 mcg added every 1 to 2 weeks as tolerated, and no dose in the protocol approaches 100 units, so nothing here splits across two injections. Sites are rotated systematically across abdomen, thighs, and upper arms to reduce local irritation and avoid lipohypertrophy, with the needle entering a pinched skinfold at 45 to 90 degrees, no aspiration, slow steady delivery, and a 5 to 10 second pause before withdrawal.

Results Timeline

Sequence described in the research record. Individual response varies.

• Weeks 1 to 2: 10 mcg daily, 0.1 units per injection, the opening step of the titration.
• Weeks 3 to 6: the dose moves to 20 mcg and then 50 mcg, reaching 0.5 units per injection.
• Weeks 7 to 8: 100 mcg daily, which is exactly 1 unit at this concentration.
• Weeks 9 to 16: held at 100 to 150 mcg daily, the top of the range, for the final eight weeks.
• Throughout: 10 to 20 mcg is added every 1 to 2 weeks as tolerated rather than jumping between steps.

Reconstitution Steps

1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe, so 10 mcg is 0.1 units and 150 mcg is 1.5 units.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C or colder in dry, dark conditions; long-term storage at -80 °C is optimal.
• Reconstituted: refrigerate at 2 to 8 °C and use within a few days, or aliquot and freeze. Thawed solution is not held longer than 1 to 2 days at 2 to 8 °C, and freeze-thaw cycles are avoided.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• Clean the vial stopper with alcohol and let it dry before every draw, since one reconstituted vial is entered daily across the whole course.

Supplies Needed

Planning below is based on a 16 week daily protocol with gradual titration, which is 7 injections per week and a weekly amount that climbs from 0.07 mg in the first two weeks to 0.7 to 1.05 mg once the dose reaches 100 to 150 mcg.

Peptide Vials (Ovagen, 20 mg vial):

• Total usage across the 16 weeks is recorded in the master sheet as about 13.5 mg, which a single 20 mg vial covers with excess remaining.

Insulin Syringes (U-100):

• Per week: 7 U-100 insulin syringes at one injection daily, with 30-unit or 50-unit barrels preferred for low-volume accuracy.
• Full cycle: 112 syringes across 16 weeks, so roughly 120 is a sensible order once spares are allowed for.

Bacteriostatic Water (10 mL bottles):

• Each 20 mg vial takes 2.0 mL of bacteriostatic water, so one 10 mL bottle covers 5 vials; the 16 week protocol uses a single vial and therefore a single bottle.

Alcohol Swabs:

• Per injection: 2 alcohol swabs, one for the vial stopper and one for the skin.
• Full cycle: 224 swabs across 112 injections, which is 3 boxes of 100.

Important Notes

Practical considerations for consistency and safety.

• Syringe choice is the practical limit here rather than the peptide. Every dose falls between 0.1 and 1.5 units, so 30-unit or 50-unit insulin syringes are used for readability, and the earliest titration steps sit at the edge of what any insulin syringe measures accurately.
• Use a new sterile insulin syringe for each injection and dispose of it in a sharps container.
• Rotate injection sites to reduce local irritation, inject slowly, and wait a few seconds before withdrawing the needle.
• Document the daily dose and the site rotation to keep a 16 week course consistent.
• Label the vial with the date and time of reconstitution, the diluent volume, the final concentration, and initials.
• Regulatory Note: Ovagen is not an approved drug for any indication and no controlled human trials exist, so the available evidence is preclinical and cell-based. The master sheet records no WADA status for this compound. For research use only; not for human consumption.

How This Works

Ovagen (EDL) is an ultrashort peptide believed to enter cells and bind DNA, thereby modulating gene expression and protein synthesis. In vitro studies show EDL increases cell proliferation and alters aging-related gene markers (p16, p21, p53, SIRT-6) in renal cell cultures, which points toward cytoprotective effects. Ultrashort peptides of this class are known to influence cell differentiation, proliferation, and apoptosis through gene regulation. EDL has also been identified as an HIV-1 protease inhibitor with binding affinity in the enzyme active site.

Benefits & Side Effects

Observations from the published record.

• May support gastrointestinal and hepatic tissue bioregulation, based on ultrashort peptide research rather than on direct clinical evidence.
• In vitro studies indicate potential cytoprotective effects through modulation of aging-related gene expression (p16, p21, p53, SIRT-6).
• Ultrashort peptides generally show rapid metabolism and low immunogenicity.
• Side effects are not well characterized because human clinical data are absent; mild injection-site reactions may occur.
• The evidence base is the main limitation. No controlled human trials exist, and the proliferation and gene expression findings come from renal cell culture rather than from gastrointestinal or hepatic tissue in a living system.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a balanced diet supporting gastrointestinal and liver health.
• Maintain regular physical activity to support overall metabolic function.
• Prioritize sleep and stress management to support adherence and recovery.
• Avoid excessive alcohol and hepatotoxic substances during the protocol.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Khavinson et al. Tripeptides slow down aging process in renal cell culture (Advances in Gerontology, 2014).
2. Velazquez-Campoy A, Freire E. HIV-1 protease inhibitors Glu-Asp-Leu thermodynamic studies (Biochemistry, 2000).